Recently, ERβ activation has been reported to be involved in insulin secretion, resistance and in glucose uptake, defining ER involvement in T2DM etiology and suggesting ERβ as a therapeutic target for T2DM management [113]. This evidence concerns the gene INS and type 2 diabetes mellitus.